|
|
Volumn 374, Issue 9691, 2009, Pages 681-
|
|
Rivaroxaban versus enoxaparin after total knee arthroplasty
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DABIGATRAN;
ENOXAPARIN;
RIVAROXABAN;
ANTICOAGULANT AGENT;
MORPHOLINE DERIVATIVE;
THIOPHENE DERIVATIVE;
CLINICAL TRIAL;
DOSAGE SCHEDULE COMPARISON;
DOSE RESPONSE;
DRUG APPROVAL;
DRUG DOSE COMPARISON;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
DRUG HALF LIFE;
EUROPE;
HUMAN;
LETTER;
NORTH AMERICA;
PRIORITY JOURNAL;
RISK FACTOR;
TOTAL KNEE REPLACEMENT;
VENOUS THROMBOEMBOLISM;
DRUG ADMINISTRATION;
KNEE ARTHROPLASTY;
METHODOLOGY;
NOTE;
VEIN THROMBOSIS;
ANTICOAGULANTS;
ARTHROPLASTY, REPLACEMENT, KNEE;
DRUG ADMINISTRATION SCHEDULE;
ENOXAPARIN;
HUMANS;
MORPHOLINES;
RESEARCH DESIGN;
THIOPHENES;
VENOUS THROMBOSIS;
|
|
EID: 69149083480
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(09)61550-6 Document Type: Letter |
|
Times cited : (5)
|
|
References (2)
|
